Assignee
GENERATION BIO CO
US·8 granted patents·42 pending applications·1 citations·filing 2018–2025
Top patents by PatentIndex Score
50 records- 0185US12263228B2Lipids and compositions thereofGENERATION BIO CO·Filed 2024·Granted Apr 1, 2025·1 cites·30 claims
- 0279US12252470B2Lipids and nanoparticle compositions thereofGENERATION BIO CO·Filed 2024·Granted Mar 18, 2025·0 cites·20 claims
- 0379US2025000071A1Identifying and characterizing genomic safe harbors (gsh) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified gsh lociGENERATION BIO CO·Filed 2024·Application pending·0 cites
- 0467US12534435B2Lipids and nanoparticle compositions thereofGENERATION BIO CO·Filed 2021·Granted Jan 27, 2026·0 cites·30 claims
- 0567US2024226325A1Cationic lipids and compositions thereofGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 0666US2025249123A1Lipids and compositions thereofGENERATION BIO CO·Filed 2025·Application pending·0 cites
- 0762US2025282848A1Non-viral dna vectors and uses thereof for expressing fviii therapeuticsGENERATION BIO CO·Filed 2025·Application pending·0 cites
- 0861US2025352666A1Lipid nanoparticle compositions and uses thereofGENERATION BIO CO·Filed 2023·Application pending·0 cites
- 0961US2025361208A1Lipids and nanoparticle compositions thereofGENERATION BIO CO·Filed 2025·Application pending·0 cites
- 1059US2020390072A1Identifying and characterizing genomic safe harbors (gsh) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified gsh lociGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 1158US12338275B2Non-viral DNA vectors and uses thereof for expressing FVIII therapeuticsGENERATION BIO CO·Filed 2020·Granted Jun 24, 2025·0 cites·17 claims
- 1258US2024261395A1Lyophilized non-viral dna vector compositions and uses thereofGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 1357US2024277833A1Non-viral dna vectors for vaccine deliveryGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 1455US2024181085A1Non-viral dna vectors and uses thereof for expressing pfic therapeuticsGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 1555US2024299580A1Apoe and apob modified lipid nanoparticle compositions and uses thereofGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 1654US12415002B2Non-viral DNA vectors and uses thereof for expressing phenylalanine hydroxylase (PAH) therapeuticsGENERATION BIO CO·Filed 2020·Granted Sep 16, 2025·0 cites·21 claims
- 1754US2022175968A1Non-active lipid nanoparticles with non-viral, capsid free dnaGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 1854US2024226324A1Non-viral dna vectors expressing therapeutic antibodies and uses thereofGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 1953US2023320993A1Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereofGENERATION BIO CO·Filed 2021·Application pending·0 cites
- 2053US2024293574A1Cationic lipids and compositions thereofGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 2152US2024216535A1Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereofGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 2252US2024382432A1Single chain variable fragment (scfv) modified lipid nanoparticle compositions and uses thereofGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 2352US2022127625A1Modulation of rep protein activity in closed-ended dna (cedna) productionGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 2452US2023134550A1Non-viral dna vectors and uses thereof for expressing gaucher therapeuticsGENERATION BIO CO·Filed 2021·Application pending·0 cites
- 2550US2023181764A1Novel lipids and nanoparticle compositions thereofGENERATION BIO CO·Filed 2021·Application pending·0 cites
- 2650US2023383311A1Non-viral dna vectors and uses thereof for expressing fviii therapeuticsGENERATION BIO CO·Filed 2021·Application pending·0 cites
- 2749US2024026374A1Closed-ended dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah)GENERATION BIO CO·Filed 2021·Application pending·0 cites
- 2849US2026041785A1Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the sameGENERATION BIO CO·Filed 2025·Application pending·0 cites
- 2949US2021054405A1Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomesGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 3049US2021388379A1Modified closed-ended dna (cedna) comprising symmetrical modified inverted terminal repeatsGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 3148US2026055426A1CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOFGENERATION BIO CO·Filed 2023·Application pending·0 cites
- 3248US2023138409A1Non-viral dna vectors and uses thereof for expressing factor ix therapeuticsGENERATION BIO CO·Filed 2021·Application pending·0 cites
- 3348US2022119840A1Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune responseGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 3447US2025281647A1Stealth lipid nanoparticle compositions for cell targetingGENERATION BIO CO·Filed 2025·Application pending·0 cites
- 3547US2022370357A1Ionizable lipids and nanoparticle compositions thereofGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 3646US12577573B2Synthetic production of single-stranded adeno associated viral DNA vectorsGENERATION BIO CO·Filed 2020·Granted Mar 17, 2026·0 cites·23 claims
- 3746US2022228171A1Compositions and production of nicked closed-ended dna vectorsGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 3845US2022280427A1Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereofGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 3945US2022184231A1Closed-ended dna (cedna) and immune modulating compoundsGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 4045US2025049961A1Scalable and high-purity cell-free synthesis of closed-ended dna vectorsGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 4144US2021059953A1Lipid nanoparticle formulations of non-viral, capsid-free dna vectorsGENERATION BIO CO·Filed 2018·Application pending·0 cites
- 4244US2024398990A1Liver-specific expression cassettes, vectors and uses thereof for expressing therapeutic proteinsGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 4343US2022288231A1Methods and compositions for reducing gene or nucleic acid therapy-related immune responsesGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 4442US12442015B2Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectorsGENERATION BIO CO·Filed 2019·Granted Oct 14, 2025·0 cites·16 claims
- 4542US2020283794A1Modified closed-ended dna (cedna)GENERATION BIO CO·Filed 2018·Application pending·0 cites
- 4642US2022042035A1Non-viral dna vectors and uses thereof for antibody and fusion protein productionGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 4741US2022175970A1Controlled expression of transgenes using closed-ended dna (cedna) vectorsGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 4841US2022290186A1Gene editing using a modified closed-ended dna (cedna)GENERATION BIO CO·Filed 2018·Application pending·0 cites
- 4941US2026041643A1Stealth lipid nanoparticle compositions for cell targetingGENERATION BIO CO·Filed 2025·Application pending·0 cites
- 5030US12453706B2Bispecific stealth lipid nanoparticle compositions for cell targetingGENERATION BIO CO·Filed 2025·Granted Oct 28, 2025·0 cites·30 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →